Stepping down against stopping: two decisions treated as one

What can be said with confidence is narrow, and it is worth separating from what is merely plausible. A gradual reduction will not prevent regain: the withdrawal trials establish that ongoing exposure is what holds the weight, and nothing about the schedule on which a drug is removed alters the homeostatic drive that reasserts itself once it is gone. A gradual reduction may nevertheless make the transition more manageable, and a person who finds it so has not been misled. Those two statements are not in tension. Coverage of this subject frequently presents them as though they were, and readers arrive at this department having been told either that tapering is essential or that it is nonsense.

The case for tapering, stated as fairly as we can

There is no withdrawal syndrome from these agents, no dependence, and no pharmacological reason to reduce gradually rather than to stop. A seven-day half-life produces its own taper: concentrations halve within a week and fall to a few per cent within a month regardless of intent. On the pharmacology alone, a planned taper accomplishes nothing that stopping does not.

The behavioural argument is different and better. Appetite returns over weeks. A person whose dose is reduced in steps experiences that return in stages, while continuing to have some pharmacological support, and has a window in which to establish eating patterns that will have to hold without the drug. A person who stops outright experiences the same return without that window. Whether the window produces better outcomes is an empirical question that has not been asked in a trial.

The Journal’s position is that the behavioural argument is worth making on its own terms and worth not dressing in pharmacological clothing. What a taper cannot do is prevent regain, since the withdrawal trials establish that ongoing exposure is what holds the weight. Presenting a taper as a way of stopping without regaining is a claim the evidence does not support in any form.

The first six weeks after the last injection

Exposure falls on a predictable schedule. A week after a final weekly injection roughly half the steady-state concentration remains; at two weeks a quarter; at four weeks a few per cent. Appetite returns along a curve that lags the concentration curve somewhat, and delayed gastric emptying resolves over a similar interval, so the sensation of early fullness that has been governing meal size for months disappears over about a month.

What people report, and the Journal reports it as report rather than as measurement, is that the appetite return is experienced as abrupt rather than gradual — as a threshold being crossed somewhere in the third or fourth week rather than as a smooth ramp. That is consistent with a non-linear relationship between receptor occupancy and the perceived effect, which is what the dose-response data would predict, and it is not consistent with the exposure curve alone.

Glycaemic parameters follow their own timescale. Fasting glucose responds within days to weeks; HbA1c, which reflects the preceding three months with the recent weeks weighted most heavily, will not show the full consequence of stopping for a full quarter. A panel drawn four weeks after cessation will understate the change, and this is a specific and common misreading. In the trial population with type 2 diabetes, where glycaemic control was a co-primary concern, the treatment effect on HbA1c was of the order of one and a half percentage points, which is the scale of what a cessation eventually undoes.¹

The lifestyle intervention is a confound in both directions

Every trial in this class delivers a behavioural intervention alongside the drug: energy-restriction targets, activity targets, and regular contact with a study team. That contact is itself an intervention of measurable effect, which is why placebo arms in these programmes lose two to three per cent of body weight rather than nothing. Where the behavioural component was deliberately intensified, the placebo arm lost around 5.7 per cent over sixty-eight weeks, which is a useful upper bound on what contact and counselling alone achieved in these populations.²

It matters for the withdrawal question in a way that is usually elided. The semaglutide off-treatment extension withdrew the drug and the lifestyle support together, so its regain figure describes the removal of a package.³ The STEP 4 and SURMOUNT-4 withdrawal arms kept the lifestyle component running, so their regain figures describe the removal of a molecule with support maintained.⁴⁵ Those are different experiments and the second is the more conservative.

Anybody comparing regain figures across the three should therefore expect the extension to look worse, and it does. The Journal states which withdrawal design a figure comes from every time it quotes one, because the alternative is pooling two different experiments into a single number that describes neither. The same caution applies to the frequent comparison with dietary weight-loss regain, where the behavioural intervention is the whole of the treatment.

Participants who complete a run-in and are then randomised are a selected group by construction, so the withdrawal arm is populated by people who both tolerated and responded. Generalising from them overstates what is known.

What would settle the maintenance question

The Journal’s position is that three trials would resolve almost everything currently argued about in this area, and that all three are straightforward. The first is a dose-reduction design: after a lead-in to target, randomise to full dose, one step down, two steps down, or placebo, and follow for a year with weight as the primary endpoint. It would establish the shape of the descending dose-response curve and would cost a fraction of a pivotal programme.

The second is an interval design: after a lead-in, randomise to weekly, fortnightly and three-weekly administration at the same nominal dose. It would answer the intermittent-schedule question directly and would settle whether the exposure pattern matters independently of average exposure.

The third is a taper design: randomise abrupt cessation against a stepped reduction over twelve weeks, with appetite, eating behaviour and weight measured for a year afterwards. It would test the only argument for tapering that is worth testing.

None of the three is under way as far as the Journal can establish. Readers who know otherwise should write to letters@compoundjournal.com; a registered protocol for any of them would be news in this department.

How the Journal reports a regain figure

Four things accompany every regain number in these pages. Which withdrawal design it comes from, because an off-treatment extension and a randomised placebo switch are different experiments. Whether the lifestyle intervention continued in the arm being described. What the denominator is — regain as a percentage of body weight, as a percentage of the weight lost, or as a final position relative to original baseline, three quantities that are routinely quoted interchangeably. And the follow-up duration, because the regain curve decelerates and a figure at six months is not a figure at a year.

The third of those is where most of the misreporting happens. A statement that participants regained two-thirds is a proportion of loss; a statement that they regained eleven per cent is a proportion of body weight; a statement that they finished 5.6 per cent below baseline is a final position. All three can describe the same arm and they are not interchangeable.

Where a source we are quoting has not stated its denominator, we say that rather than inferring it. Readers who find a regain figure in these pages without its design and its denominator have found an error, and the standards desk would like to hear about it at standards@compoundjournal.com.

Maintenance has a thinner evidence base than escalation, which is the opposite of where people spend their time. That imbalance is the largest gap between what has been studied and what is lived, and it is not closing quickly.

What this piece is not

This is reporting on a body of trial evidence and it is not advice about whether or how to stop taking a medicine. The decision to discontinue an agent prescribed for glycaemic control, cardiovascular risk or kidney disease is materially different from the decision to discontinue one prescribed for weight, and in every case it belongs with a clinician who has seen the person and knows why the drug was started.

Two further notes. Compounds sold for research use only are not approved for human use in any jurisdiction, and nothing here should be read as guidance about using them or about stopping their use. And where this piece describes what clinicians report doing about maintenance dosing, that is description of practice and not a schedule anybody should adopt from a magazine.

The Journal takes correspondence on this subject at letters@compoundjournal.com and factual challenges at standards@compoundjournal.com. Letters describing a personal experience of stopping are read with attention and are published, where they are published, as accounts rather than as evidence — a distinction this department tries hard to preserve in both directions.

The stopping question has a clear answer and an unclear set of consequences. Treatment maintains weight loss while it continues; stopping abruptly returns most but not all of the lost weight within a year; and nothing in the randomised record supports the claim that a person ends up worse off than they started. What is genuinely unresolved is everything between full dose and nothing, which is where almost every real decision is made.